FDA Determines Regulatory Review Period for VISTIDE Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for VISTIDE, a human drug product, in response to a patent extension application submitted to the U.S. Patent and Trademark Office.